Exchange: NASDAQ·Updated 07:42 PM EDT
News
all
press releases
HALO Stock Rises 36% in a Month: Here's What You Should Know
Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.
Zacks
More News
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. RL, AMP, HALO and NVDA are some such stocks.
Zacks
Halozyme Appoints Dannielle Appelhans to its Board of Directors
Halozyme Appoints Dannielle Appelhans to its Board of Directors Halozyme Appoints Dannielle Appelhans to its Board of Directors PR Newswire SAN DIEGO, Aug. 18, 2026 SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced the election of...
PR Newswire
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?
Here is how Halozyme Therapeutics (HALO) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Zacks
These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months
Natera and Halozyme Therapeutics saw gains above 15%, led by bullish Wall Street commentary after better-than-expected second-quarter results.
Stocktwits
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up
HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.
Zacks
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.28% and +17.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE PR Newswire SAN DIEGO, Aug. 6, 2026 Total Revenue Increased 48% YOY to...
PR Newswire

Advertisement|Remove ads.